Lincoln International’s Global Healthcare Group Announces Record Year

Lincoln International remains one of the most active healthcare M&A advisors in 2021

Lincoln International’s global healthcare mergers and acquisitions (M&A) activity in 2021 eclipsed that of 2020 led by the firm’s growing sector capabilities and strong appetite for deals. In 2021, we completed transactions with or on behalf of some of the largest and most well-known names in healthcare private equity. Lincoln’s reputation for advising on, executing and closing high-quality assignments across healthcare services, life sciences, pharma outsourcing, medical products and healthcare information technology (IT) continues to strengthen. Lincoln is one of the only investment banks with dedicated, senior healthcare bankers covering markets across the Americas, Europe and Asia.


  • Lincoln International's global Healthcare Group celebrates record results in 2021.

Select Notable 2021 Healthcare Transactions

Related Perspectives

Real Deals | Healthcare M&A Resilience

What trends have you seen in the last quarter in relation to valuations in the healthcare space? Matthew Lee: It’s early days to get an accurate read on valuations as… Read More

Lincoln International Announces Strategic Partnership with Australian Corporate Advisory Firm, Miles Advisory Partners

Lincoln International, a global investment banking advisory firm, announced today that it has established a strategic partnership with Miles Advisory Partners, an Australian-based independent corporate advisory firm, servicing the robust… Read More

Lincoln International’s Global Healthcare Group Announces Strong Results in 2022

Lincoln International’s global Healthcare Group enjoyed another consecutive year of record-setting mergers and acquisitions (M&A) deal volume, average deal size and a record backlog heading in to 2023. Our performance… Read More

Scrip | What Does 2023 Hold for Biopharma? Part 6: Artificial Intelligence

Originally posted by Scrip on February 10, 2023. Tony Crisman, Managing Director in Lincoln’s Healthcare Group, shares his predictions for artificial intelligence in the biopharma industry. View the original article.

Meet Our Senior Team